NAA11

Across TCGA pan-cancer cohorts, NAA11 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NAA11 data layer compared with 15 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher NAA11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NAA11 expression acts as an unfavorable survival marker.

DLBC, ESCA, and LGG are the cancer types where NAA11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
ESCA	DFS	Median	All	0.151	0.541	<.001	24	view →
LGG	OS	Median	All	0.176	0.812	<.001	18	view →
LUSC	OS	Median	II,III,IV	0.283	0.633	.021	15	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NAA11–DLBC (OS)

Open the DLBC breakdown →